Quantcast
Last updated on April 19, 2014 at 21:20 EDT

Latest Mucositis Stories

2013-05-22 23:22:41

It´s estimated that 400,000 of 1.2 million Americans diagnosed with cancer yearly may develop painful oral complications from treatment. For Cancer Awareness Month, MedActive emphasizes their commitment to provide quality solutions for cancer patients in need of oral relief and oral care. Spring Hill, FL (PRWEB) May 22, 2013 May is Cancer Awareness Month and as a leading provider of oral care and relief products, MedActive is emphasizing its support of cancer patients and survivors....

2013-05-16 08:28:35

MuGard Gross Revenues Up 118% Quarter-on-Quarter and Over 20% from Q4 2012 DALLAS and NEW YORK, May 16, 2013 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, released its first quarter ended March 31, 2013 financial results. The company indicated it will host a conference call at a later date to review financial results and ongoing commercial MuGard progress made within the quarter. MuGard, Access' lead product, is a novel;...

2013-05-03 08:25:23

PRINCETON, N.J., May 3, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today its financial results for the quarter ended March 31, 2013. Soligenix's revenues for the quarter ended March 31, 2013 were $0.9 million as compared to $0.6 million for the first quarter of 2012....

2013-05-02 23:15:21

Invado Pharmaceuticals announced that Cleveland Clinic Cancer Clinic presented positive clinical data on NeutraSal at ONS World Congress Meeting in Washington DC. The data suggested that NeutraSal is more effective than salt and soda rinses in reducing oral toxicities in head and neck cancer patients. Pomona, NY (PRWEB) May 02, 2013 Invado Pharmaceuticals announced that Jean Hamker, RN of the Cleveland Clinic Taussig Cancer Institute presented data from a NeutraSal study at last week's ONS...

2013-04-29 08:28:12

128 Patient MuGard Study Underscores the Powerful Clinical Impact MuGard Provides Cancer Patients Suffering with Oral Mucositis DALLAS and NEW YORK, April 29, 2013 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, announced that Carrie Daly, MS, RN, APN, AOCN of Rush University Medical Center presented data from a MuGard study, performed by the Institution, at last week's Oncology Nursing Society Annual Congress in Washington, DC....

2013-04-15 23:00:09

Midtown Dentistry treats patients undergoing radiation treatment to the head using the latest "Oral Health in Cancer Therapy" guide that describes the latest treatments and medications for oral health during radiation. Houston, TX (PRWEB) April 15, 2013 With our aging population, more people receive radiation treatment and need private care for the side effects. Midtown Dentistry is part of a new wave of dentists offering private care for radiation complications and medications to help the...

2013-03-27 08:31:27

PRINCETON, N.J., March 27, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company, announced today that the Food and Drug Administration (FDA) has completed its review and cleared the Investigational New Drug (IND) application for SGX942 for the treatment of oral mucositis resulting from radiation and/or chemotherapy treatment in head and neck cancer patients. Clearance of the IND allows Soligenix to initiate a Phase 2,...

2013-03-20 08:27:28

MuGard Gross Revenues up 586% year-on-year, and 256% quarter-on-quarter DALLAS and NEW YORK, March 20, 2013 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, will host an investor call to update investors on financial results for the quarter and the fiscal year ended December 31, 2012. The company will also review ongoing commercial activities and progress made within its MuGard program. MuGard, Access' lead product, is a...

2013-02-20 08:28:05

PRINCETON, N.J., Feb. 20, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today submission of a full contract proposal to the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Biological, Radiological and Nuclear (CBRN) Medical Countermeasures. This submission supports a potential multi-year, multi-million dollar contract to develop OrbeShield(TM) (oral beclomethasone...

2013-02-04 08:25:21

PRINCETON, N.J., Feb. 4, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a development-stage biopharmaceutical company, announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it advances the development of SGX942 for the treatment of oral mucositis, a common complication of cancer treatments. Comprised of cancer supportive care thought leaders with extensive experience in oral mucositis,...